Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7287103 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7287099 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22779705 | 0.86 | — | — | |
| SCHEMBL11794881 | 0.81 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL9432212 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL10565853 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL10565859 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL11792753 | 0.75 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL498419 | 0.75 | NAAA (0.40) | ALDH1A1 | |
| SCHEMBL498418 | 0.75 | NAAA (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2022-10-11 | — | — | US | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20190151336-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
| US-10245275-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2019-04-02 | — | — | US | disclosed |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-30 | — | — | US | disclosed |
| EP-2814834-B1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-2814834-B1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| US-20170056420-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2017-03-02 | — | — | US | disclosed |
| US-9527882-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| WO-2015157483-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| EP-2576586-B1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2814834-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | Bristol-Myers Squibb Company (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8906889-B2 | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8802661-B2 | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-12 | — | — | US | disclosed |
| WO-2013123019-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130210787-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-20190151336-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-10245275-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | ERG28, BET1, BRD3 | ALDH1A1 3288/4885 |
| US-20130210787-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, ZC3HAV1, CYP8B1 | ALDH1A1 2192/4885 |
| US-20170056420-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.